Lisa Henderson

Tackling some of the unintended consequences associated with value-based contracting in pharma and efforts to advance toward sustainable outcomes-based engagement.

Pharm Exec chronicles the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader-a C-suite must in reviving the industry’s beleaguered reputation.

Drawing parallels from the world of football coaching in evaluating and grooming future C-suite pharma leaders-call it the quest to see "what right looks like?"

The advent of immunocellular therapies marks a major milestone in pharma, but the path for these treatments in transforming patient care is still forming as they face challenges in clinical trials, pricing, and market acceptance,

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.

Drawing from his research roots and the leadership lessons gained in melding business and culture in geographies across the globe, Ruud Dobber is busy steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.

Our annual look at the drug industry's pipeline-the progress and the setbacks-puts my thoughts on those people driving new science behind the scenes in pharmaceutical research.

As we again highlight a roster of emerging leaders in pharma, I wanted to recognize Pharm Exec's own unique team behind the scenes.

A big thank you to you, our readers, for lending your voice to Pharm Exec's editorial mission-giving you the information you need and want. Click ahead for a look at some of the future topics we'll be tackling.

As more states approve the use of medical marijuana-and its rising profile as potential opioid alternative-industry and FDA are stepping up their focus on developing cannabis-derived therapies.

There's no shortage of talent, expertise and passion in the biopharma industry. It's time for that talent to shine.

Two topics in Pharm Exec this month-rare disease research and women in healthcare leadership-share a "common" thread.

Here's to hoping that PhRMA's new public education campaign advances the voice of the patient in its messaging.

Recent events you may have missed on the global pharma scene.

Lisa Henderson discusses how role of social media in post-market adverse event reporting is finally being taken seriously by the FDA.

In December 2011, the President’s Bioethics Commission released its “Moral Science: Protecting Participants in Human Subjects Research“